JP2022500389A5 - - Google Patents

Info

Publication number
JP2022500389A5
JP2022500389A5 JP2021513344A JP2021513344A JP2022500389A5 JP 2022500389 A5 JP2022500389 A5 JP 2022500389A5 JP 2021513344 A JP2021513344 A JP 2021513344A JP 2021513344 A JP2021513344 A JP 2021513344A JP 2022500389 A5 JP2022500389 A5 JP 2022500389A5
Authority
JP
Japan
Prior art keywords
drug
seq
sequence
protein
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021513344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500389A (ja
JP7629394B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/074101 external-priority patent/WO2020053206A1/en
Publication of JP2022500389A publication Critical patent/JP2022500389A/ja
Publication of JP2022500389A5 publication Critical patent/JP2022500389A5/ja
Application granted granted Critical
Publication of JP7629394B2 publication Critical patent/JP7629394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021513344A 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン Active JP7629394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862729068P 2018-09-10 2018-09-10
US62/729,068 2018-09-10
PCT/EP2019/074101 WO2020053206A1 (en) 2018-09-10 2019-09-10 Coversin for use in the treatment of rheumatic diseases

Publications (3)

Publication Number Publication Date
JP2022500389A JP2022500389A (ja) 2022-01-04
JP2022500389A5 true JP2022500389A5 (cg-RX-API-DMAC10.html) 2022-09-09
JP7629394B2 JP7629394B2 (ja) 2025-02-13

Family

ID=67988965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513344A Active JP7629394B2 (ja) 2018-09-10 2019-09-10 リウマチ性疾患の治療に使用するためのコバーシン

Country Status (4)

Country Link
US (2) US20220047673A1 (cg-RX-API-DMAC10.html)
EP (1) EP3849588A1 (cg-RX-API-DMAC10.html)
JP (1) JP7629394B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020053206A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) * 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
GB202408081D0 (en) 2024-06-06 2024-07-24 Volution Immuno Pharmaceuticals Sa Methods of removing impurities

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3729295A (en) * 1994-09-23 1996-04-09 Alexion Pharmaceuticals, Inc. Methods for the treatment of inflammatory joint disease
US7884188B2 (en) 2003-06-02 2011-02-08 Varleigh Immuno Pharmaceuticals (Vip) Ltd Complement inhibitors
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
EP2061501B1 (en) * 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
GB0802116D0 (en) * 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
CA2785612C (en) * 2010-01-08 2019-09-10 Varleigh Immuno Pharmaceuticals (Vip) Ltd. Ev576 for use in the treatment of viral infections of the respiratory tract
JP6505079B2 (ja) * 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
CA3177696A1 (en) 2014-02-20 2015-08-27 Allergan, Inc. Complement component c5 antibodies
WO2016198133A1 (en) 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
GB201706406D0 (en) * 2017-04-21 2017-06-07 Volution Immuno Pharmaceuticals Sa Method of treatment
JP7209637B2 (ja) * 2017-04-21 2023-01-20 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 自己免疫性水疱症の治療のためのコバーシン

Similar Documents

Publication Publication Date Title
Pines et al. Cloning and expression of a rat brain L-glutamate transporter
US8318172B2 (en) Breaking immunological tolerance with a genetically encoded unnatural amino acid
TWI701041B (zh) 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
CN111533809A (zh) 针对新型冠状病毒的亚单位疫苗及应用
CN104684571B (zh) 新的il‑17a结合分子及其医学应用
JPH10500568A (ja) Ｔｎｆ／ｎｇｆスーパーファミリー受容体および可溶性オリゴマー ｔｎｆ／ｎｇｆスーパーファミリー受容体のモジュレーター
KR20250040096A (ko) Hbv 백신 및 hbv를 치료하는 방법
JP2018537418A5 (cg-RX-API-DMAC10.html)
MXPA05012497A (es) Composiciones y metodos para el tratamiento del sindrome respiratorio agudo severo (sars).
KR20170120616A (ko) 염증성 질환의 치료 방법
Zhao et al. Research on liver damage caused by the treatment of rheumatoid arthritis with novel biological agents or targeted agents
US20250195612A1 (en) Coversin for use in the treatment of rheumatic diseases
TW416960B (en) Reshaped human antibody to human interleukin-8
ES2253824T3 (es) Anticuerpos cataliticos y un metodo para producir los mismos.
EP1572065A2 (en) Method and pharmaceutical composition for the treatment of multiple sclerosis
Cavagna et al. The emerging role of biotechnological drugs in the treatment of gout
US20230310409A1 (en) Treating rheumatoid arthritis
TWI465460B (zh) 用於治療病毒感染及癌症之新穎醫藥組合物
JP2022529266A5 (cg-RX-API-DMAC10.html)
Sharma et al. Biologics in rheumatoid arthritis
US20220062372A1 (en) Methods for treating disease and reducing drug-induced liver injury in patient populations
KR101625112B1 (ko) 아이케이 인자 및 아이케이 인자를 코딩하는 핵산의 약학적 용도
CN113454107A (zh) 具有改善的治疗效果的依那西普变体
US7060682B2 (en) Receptor recognition factors, protein sequences and methods of use thereof
TADA et al. New Therapy in Rheumatoid Arthritis Biological DMARDs and JAK Inhibitors